vs
MYR GROUP INC.（MYRG）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
MYR GROUP INC.的季度营收约是登士柏西诺德的1.0倍（$973.5M vs $961.0M），MYR GROUP INC.净利率更高（3.8% vs -15.2%，领先18.9%），MYR GROUP INC.同比增速更快（17.3% vs 6.2%），MYR GROUP INC.自由现金流更多（$84.9M vs $60.0M），过去两年MYR GROUP INC.的营收复合增速更高（9.3% vs 0.4%）
MYR集团是美国知名电气建设服务提供商，业务覆盖输配电线路、变电站、工商业建筑及可再生能源领域的电气施工，旗下拥有12家电气建设子公司，在北美电力基建赛道拥有深厚的技术积累与项目交付能力。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
MYRG vs XRAY — 直观对比
营收规模更大
MYRG
是对方的1.0倍
$961.0M
营收增速更快
MYRG
高出11.1%
6.2%
净利率更高
MYRG
高出18.9%
-15.2%
自由现金流更多
MYRG
多$24.9M
$60.0M
两年增速更快
MYRG
近两年复合增速
0.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $973.5M | $961.0M |
| 净利润 | $36.5M | $-146.0M |
| 毛利率 | 11.4% | 46.1% |
| 营业利润率 | 4.8% | -14.5% |
| 净利率 | 3.8% | -15.2% |
| 营收同比 | 17.3% | 6.2% |
| 净利润同比 | 129.1% | 66.0% |
| 每股收益（稀释后） | $2.33 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MYRGXRAY
| Q4 25 | $973.5M | $961.0M | ||
| Q3 25 | $950.4M | $904.0M | ||
| Q2 25 | $900.3M | $936.0M | ||
| Q1 25 | $833.6M | $879.0M | ||
| Q4 24 | $829.8M | $905.0M | ||
| Q3 24 | $888.0M | $951.0M | ||
| Q2 24 | $828.9M | $984.0M | ||
| Q1 24 | $815.6M | $953.0M |
净利润MYRGXRAY
| Q4 25 | $36.5M | $-146.0M | ||
| Q3 25 | $32.1M | $-427.0M | ||
| Q2 25 | $26.5M | $-45.0M | ||
| Q1 25 | $23.3M | $20.0M | ||
| Q4 24 | $16.0M | $-430.0M | ||
| Q3 24 | $10.6M | $-494.0M | ||
| Q2 24 | $-15.3M | $-4.0M | ||
| Q1 24 | $18.9M | $18.0M |
毛利率MYRGXRAY
| Q4 25 | 11.4% | 46.1% | ||
| Q3 25 | 11.8% | 48.8% | ||
| Q2 25 | 11.5% | 52.4% | ||
| Q1 25 | 11.6% | 53.0% | ||
| Q4 24 | 10.4% | 49.3% | ||
| Q3 24 | 8.7% | 52.1% | ||
| Q2 24 | 4.9% | 51.9% | ||
| Q1 24 | 10.6% | 53.1% |
营业利润率MYRGXRAY
| Q4 25 | 4.8% | -14.5% | ||
| Q3 25 | 4.9% | -24.1% | ||
| Q2 25 | 4.4% | -13.7% | ||
| Q1 25 | 4.1% | 7.2% | ||
| Q4 24 | 3.6% | -56.2% | ||
| Q3 24 | 2.3% | -48.6% | ||
| Q2 24 | -2.5% | 5.1% | ||
| Q1 24 | 3.0% | 4.4% |
净利率MYRGXRAY
| Q4 25 | 3.8% | -15.2% | ||
| Q3 25 | 3.4% | -47.2% | ||
| Q2 25 | 2.9% | -4.8% | ||
| Q1 25 | 2.8% | 2.3% | ||
| Q4 24 | 1.9% | -47.5% | ||
| Q3 24 | 1.2% | -51.9% | ||
| Q2 24 | -1.8% | -0.4% | ||
| Q1 24 | 2.3% | 1.9% |
每股收益（稀释后）MYRGXRAY
| Q4 25 | $2.33 | $-0.74 | ||
| Q3 25 | $2.05 | $-2.14 | ||
| Q2 25 | $1.70 | $-0.22 | ||
| Q1 25 | $1.45 | $0.10 | ||
| Q4 24 | $0.97 | $-2.09 | ||
| Q3 24 | $0.65 | $-2.46 | ||
| Q2 24 | $-0.91 | $-0.02 | ||
| Q1 24 | $1.12 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $150.2M | $326.0M |
| 总债务越低越好 | $59.0M | $2.3B |
| 股东权益账面价值 | $660.4M | $1.3B |
| 总资产 | $1.6B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.09× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资MYRGXRAY
| Q4 25 | $150.2M | $326.0M | ||
| Q3 25 | $76.2M | $363.0M | ||
| Q2 25 | $23.0M | $359.0M | ||
| Q1 25 | $10.9M | $398.0M | ||
| Q4 24 | $3.5M | $272.0M | ||
| Q3 24 | $7.6M | $296.0M | ||
| Q2 24 | $1.9M | $279.0M | ||
| Q1 24 | $3.9M | $291.0M |
总债务MYRGXRAY
| Q4 25 | $59.0M | $2.3B | ||
| Q3 25 | $72.0M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $87.2M | — | ||
| Q4 24 | $74.4M | $1.7B | ||
| Q3 24 | $93.2M | — | ||
| Q2 24 | $45.1M | — | ||
| Q1 24 | $37.9M | — |
股东权益MYRGXRAY
| Q4 25 | $660.4M | $1.3B | ||
| Q3 25 | $617.6M | $1.5B | ||
| Q2 25 | $583.2M | $2.0B | ||
| Q1 25 | $548.7M | $2.0B | ||
| Q4 24 | $600.4M | $1.9B | ||
| Q3 24 | $588.5M | $2.5B | ||
| Q2 24 | $633.3M | $3.1B | ||
| Q1 24 | $663.7M | $3.3B |
总资产MYRGXRAY
| Q4 25 | $1.6B | $5.4B | ||
| Q3 25 | $1.6B | $5.7B | ||
| Q2 25 | $1.6B | $6.1B | ||
| Q1 25 | $1.5B | $6.0B | ||
| Q4 24 | $1.6B | $5.8B | ||
| Q3 24 | $1.6B | $6.6B | ||
| Q2 24 | $1.6B | $6.9B | ||
| Q1 24 | $1.6B | $7.1B |
负债/权益比MYRGXRAY
| Q4 25 | 0.09× | 1.70× | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.12× | 0.90× | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.8M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $84.9M | $60.0M |
| 自由现金流率自由现金流/营收 | 8.7% | 6.2% |
| 资本支出强度资本支出/营收 | 3.1% | 4.3% |
| 现金转化率经营现金流/净利润 | 3.14× | — |
| 过去12个月自由现金流最近4个季度 | $232.2M | $104.0M |
8季度趋势，按日历期对齐
经营现金流MYRGXRAY
| Q4 25 | $114.8M | $101.0M | ||
| Q3 25 | $95.6M | $79.0M | ||
| Q2 25 | $32.9M | $48.0M | ||
| Q1 25 | $83.3M | $7.0M | ||
| Q4 24 | $21.1M | $87.0M | ||
| Q3 24 | $35.6M | $141.0M | ||
| Q2 24 | $22.7M | $208.0M | ||
| Q1 24 | $7.7M | $25.0M |
自由现金流MYRGXRAY
| Q4 25 | $84.9M | $60.0M | ||
| Q3 25 | $65.4M | $40.0M | ||
| Q2 25 | $11.6M | $16.0M | ||
| Q1 25 | $70.2M | $-12.0M | ||
| Q4 24 | $8.8M | $36.0M | ||
| Q3 24 | $18.0M | $98.0M | ||
| Q2 24 | $2.5M | $156.0M | ||
| Q1 24 | $-18.1M | $-9.0M |
自由现金流率MYRGXRAY
| Q4 25 | 8.7% | 6.2% | ||
| Q3 25 | 6.9% | 4.4% | ||
| Q2 25 | 1.3% | 1.7% | ||
| Q1 25 | 8.4% | -1.4% | ||
| Q4 24 | 1.1% | 4.0% | ||
| Q3 24 | 2.0% | 10.3% | ||
| Q2 24 | 0.3% | 15.9% | ||
| Q1 24 | -2.2% | -0.9% |
资本支出强度MYRGXRAY
| Q4 25 | 3.1% | 4.3% | ||
| Q3 25 | 3.2% | 4.3% | ||
| Q2 25 | 2.4% | 3.4% | ||
| Q1 25 | 1.6% | 2.2% | ||
| Q4 24 | 1.5% | 5.6% | ||
| Q3 24 | 2.0% | 4.5% | ||
| Q2 24 | 2.4% | 5.3% | ||
| Q1 24 | 3.2% | 3.6% |
现金转化率MYRGXRAY
| Q4 25 | 3.14× | — | ||
| Q3 25 | 2.98× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 3.57× | 0.35× | ||
| Q4 24 | 1.32× | — | ||
| Q3 24 | 3.35× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.41× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MYRG
| Market Type Electrical Construction | $442.6M | 45% |
| Market Type Transmission | $330.3M | 34% |
| Market Type Distribution | $200.6M | 21% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
